Suraksha Diagnostic Board of Directors
Get the latest insights into the leadership at Suraksha Diagnostic. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mamta jain | Company Secretary & Compliance Officer |
| Somnath Chatterjee | Chairman & Joint Managing Director |
| Ritu Mittal | Joint Managing Director & Chief Executive Officer |
| Satish Kumar Verma | Non Independent & Non Executive Director |
| Arun Sadhanandham | Nominee Director of Orbimed Asia II Mauritius Limited |
| Pradip Kumar Dutta | Non Executive Independent Director |
| Ishani Ray | Non Executive Independent Director |
| Siddhartha Roy | Non Executive Independent Director |
| Dharam Chand Dharewa | Non Executive Independent Director |
Suraksha Diagnostic FAQs
The board at Suraksha Diagnostic consists of experienced professionals, including Mamta jain, Somnath Chatterjee, and others, overseeing the company’s strategic and corporate governance.
Directors at Suraksha Diagnostic are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mamta jain is the current chairman at Suraksha Diagnostic.
Executive directors at Suraksha Diagnostic are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Suraksha Diagnostic adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Suraksha Diagnostic, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
